Skip to main content
SpringerLink
Log in

Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

An Erratum to this article was published on 22 March 2014

Abstract

Tyrosine kinase inhibitors (TKIs) have contributed to marked improvements in survival in patients with chronic myeloid leukaemia (CML). This article discusses the place of the second-generation TKIs dasatinib and nilotinib in the first-line treatment of CML and is based on published literature. The new agents are more potent and effective than imatinib. Data from pivotal clinical trials indicate that response to dasatinib and nilotinib is greater and more rapid than that to imatinib, resulting in a higher probability of patients achieving an optimal response to treatment. Differences between the newer agents with respect to patient groups for whom caution is advised, drug interaction potential, haematological toxicity, pulmonary toxicity, changes in the immune system and effects on laboratory parameters are discussed. With similar levels of efficacy, the choice of second-generation agents should be guided by the characteristics of the individual patient and the most suitable dosing regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Rogers G, Hoyle M, Thompson Coon J, et al. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technol Assess. 2012;16(22):1–410.

    CAS  Google Scholar 

  2. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247(4944):824–30.

    Article  PubMed  CAS  Google Scholar 

  3. Heisterkamp N, Groffen J, Stephenson JR, et al. Chromosomal localization of human cellular homologues of two viral oncogenes. Nature. 1982;299(5885):747–9.

    Article  PubMed  CAS  Google Scholar 

  4. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497.

    Google Scholar 

  5. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290–3.

    Article  PubMed  CAS  Google Scholar 

  6. National Comprehensive Cancer Network. NCCN guidelines™ version 2.2012 panel members: chronic myeloid leukemia (online). http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed 16 July 2012.

  7. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12):3123–7.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2009 (vintage 2009 populations) (online). Summary based on November 2011 SEER data submission, posted to the SEER web site, April 2012. http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed 16 July 2012.

  9. Brenner H, Gondos A, Pulte D. Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica. 2008;93(10):1544–9.

    Article  PubMed  Google Scholar 

  10. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–17.

    Article  PubMed  CAS  Google Scholar 

  11. Deininger MW, O’Brien S, Guilhot F, et al. International randomized study of interferon vs ST1571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly-diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (abstract). Blood. 2009;114(22):1126.

    Google Scholar 

  12. Greig MB. Myleran in the treatment of chronic myeloid leukaemia. Acta Haematol. 1956;16(3):171–80.

    Article  PubMed  CAS  Google Scholar 

  13. Kennedy BJ, Yarbro JW. Metabolic and therapeutic effects of hydroxyurea in chronic myeloid leukemia. JAMA. 1966;195(12):1038–43.

    Article  PubMed  CAS  Google Scholar 

  14. Kantarjian HM, Keating MJ, Estey EH, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol. 1992;10(5):772–8.

    PubMed  CAS  Google Scholar 

  15. Talpaz M, Mavligit G, Keating M, et al. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med. 1983;99(6):789–92.

    Article  PubMed  CAS  Google Scholar 

  16. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–7.

    Article  PubMed  CAS  Google Scholar 

  17. O’Brien S, Berman E, Borghaei H, et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw. 2009;7(9):984–1023.

    PubMed  Google Scholar 

  18. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–70.

    Article  PubMed  CAS  Google Scholar 

  19. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–9.

    Article  PubMed  CAS  Google Scholar 

  20. Blay JY, von Mehren M. Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin Oncol. 2011;38(Suppl 1):S3–9.

    Article  PubMed  CAS  Google Scholar 

  21. Novartis Pharmaceuticals. Nilotinib (Tasigna) summary of product characteristics [online]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000798/WC500034394.pdf. Accessed 16 July 2012.

  22. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010;95(2):232–40.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  23. Bristol-Myers Squibb. Dasatinib (Sprycel) summary of product characteristics (online). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000709/WC500056998.pdf. Accessed 16 July 2012.

  24. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841–51.

    Article  PubMed  CAS  Google Scholar 

  25. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26(10):2197–203.

    Article  PubMed  CAS  Google Scholar 

  26. Clark R, Reiffers J, Kim DW, et al. Superior efficacy of nilotinib compared with imatinib in newly diagnosed patients with PH+ chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year follow-up (abstract). Haematologica. 2012;97(Suppl 1):0583.

    Google Scholar 

  27. Hochhaus A, Shah NP, Cortes JE, et al. Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up (abstract). J Clin Oncol. 2012;30(Suppl 15):6504.

    Google Scholar 

  28. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123–9.

    Article  PubMed  CAS  Google Scholar 

  29. Kannel WB. Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J. 1999;138(3 Pt 2):205–10.

    Article  PubMed  CAS  Google Scholar 

  30. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462–536.

    PubMed  Google Scholar 

  31. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.

    Article  PubMed  Google Scholar 

  32. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289(18):2363–9.

    Article  PubMed  Google Scholar 

  33. Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension. 2008;52(5):818–27.

    Article  PubMed  CAS  Google Scholar 

  34. World Health Organization. Diabetes: facts and figures (online). http://www.euro.who.int/en/what-we-do/health-topics/noncommunicable-diseases/diabetes/facts-and-figures. Accessed 16 July 2012.

  35. World Health Organization. Diabetes fact sheet #312 (online). http://www.who.int/mediacentre/factsheets/fs312/en/#. Accessed 16 July 2012.

  36. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia. 2002;45(7):S23–8.

    PubMed  CAS  Google Scholar 

  37. Saglio G, Larson RA, Hughes TP, et al. Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (pts) with type 2 diabetes in the ENESTnd trial (abstract). Blood. 2010;116:3430.

    Google Scholar 

  38. Larson RA, le Coutre P, Reiffers J, et al. Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond 1 year (abstract). J Clin Oncol. 2010;28(Suppl 15):6501.

    Google Scholar 

  39. World Health Organization. Global atlas on cardiovascular disease prevention and control (online). http://www.who.int/cardiovascular_diseases/en/. Accessed 16 July 2012.

  40. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011;86(7):610–1.

    Article  PubMed  Google Scholar 

  41. Le Coutre P, Rea D, Abruzzese E, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011;103(17):1347–8.

    Article  PubMed  CAS  Google Scholar 

  42. Levato L, Cantaffa R, Kropp MG, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol. 2013;90(6):531–2.

    Article  PubMed  CAS  Google Scholar 

  43. Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27(6):1310–5.

    Google Scholar 

  44. ARIAD Pharmaceuticals. Inclusig™ (ponatinib) tablets: package insert (online). http://www.iclusig.com/hcp/index.cfm. Accessed 5 June 2013.

  45. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–37.

    Article  PubMed  CAS  Google Scholar 

  46. Akgun KM, Crothers K, Pisani M. Epidemiology and management of common pulmonary diseases in older persons. J Gerontol A Biol Sci Med Sci. 2012;67(3):276–91.

    Article  PubMed  Google Scholar 

  47. Rycroft CE, Heyes A, Lanza L, et al. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis. 2012;7:457–94.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Bustacchini S, Chiatti C, Furneri G, et al. The economic burden of chronic obstructive pulmonary disease in the elderly: results from a systematic review of the literature. Curr Opin Pulm Med. 2011;17(Suppl 1):S35–41.

    Article  PubMed  Google Scholar 

  49. Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007;176(8):814–8.

    Article  PubMed  CAS  Google Scholar 

  50. Breccia M, Alimena G. Pleural/pericardiac effusions during dasatinib treatment: incidence, management and risk factors associated to their development. Expert Opin Drug Saf. 2010;9(5):713–21.

    Article  PubMed  CAS  Google Scholar 

  51. Quintas-Cardama A, Kantarjian H, O’Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908–14.

    Article  PubMed  CAS  Google Scholar 

  52. Brixey AG, Light RW. Pleural effusions due to dasatinib. Curr Opin Pulm Med. 2010;16(4):351–6.

    Article  PubMed  Google Scholar 

  53. de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141(5):745–7.

    Article  PubMed  Google Scholar 

  54. Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116(2):377–86.

    Article  PubMed  CAS  Google Scholar 

  55. Rea D, Bergeron A, Fieschi C, et al. Dasatinib-induced lupus. Lancet. 2008;372(9640):713–4.

    Article  PubMed  Google Scholar 

  56. Weichsel R, Dix C, Wooldridge L, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008;14(8):2484–91.

    Article  PubMed  CAS  Google Scholar 

  57. Rodriguez GH, Ahmed SI, Al-akhrass F, et al. Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications. Leuk Lymphoma. 2012;53(8):1530–5.

    Article  PubMed  CAS  Google Scholar 

  58. Abram CL, Lowell CA. The diverse functions of Src family kinases in macrophages. Front Biosci. 2008;13:4426–50.

    Article  PubMed  CAS  Google Scholar 

  59. Saltz LB. Looking ahead: what will change in colorectal cancer treatment? Gastrointest Cancer Res. 2009;3(2 Suppl):S16–8.

    PubMed Central  PubMed  Google Scholar 

  60. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83–117.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Matt Weitz and Mary Hines of in Science Communications, Springer Healthcare for providing medical writing support and Simone Boniface for providing post-submission support for this paper. This support was funded by BMS. The authors’ work and the medical writing assistance were independent of the funders. EA received honorarium for advisory board participation from Bristol-Myers Squibb and Novartis; the editorial work was done independently, Springer Healthcare provided funding support. MB received honoraria from Bristol-Myers Squibb, Celgene and Novartis. RL received funding from Bristol-Myers Squibb, Celgene, Novartis and Shire.

Author information

Authors and Affiliations

  1. Hematology, S. Eugenio Hospital, Tor Vergata University, P. le dell’Umanesimo 10, 00144, Rome, Italy

    Elisabetta Abruzzese

  2. Department of Cellular Biotechnology and Hematology, Sapienza University, Rome, Italy

    Massimo Breccia

  3. Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Via Benevento 6, Rome, Italy

    Roberto Latagliata

Authors
  1. Elisabetta Abruzzese
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Massimo Breccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberto Latagliata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elisabetta Abruzzese.

Additional information

E. Abruzzese, M. Breccia and R. Latagliata contributed equally to the paper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abruzzese, E., Breccia, M. & Latagliata, R. Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML). BioDrugs 28, 17–26 (2014). https://doi.org/10.1007/s40259-013-0056-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-013-0056-z

Keywords

Search

Navigation